Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Supernus Pharmaceuticals director Georges Gemayel reported an option exercise and related stock sales. On March 6, 2026, he exercised a director stock option for 7,905 shares, receiving common stock at an exercise price of $0.00 per share, and held 36,064 shares afterward.
He then sold 10,000 shares of common stock on March 5, 2026 at a weighted average price of about $53.71, and a further 8,787 shares on March 6, 2026 at about $53.00, in open-market transactions. After these sales, he directly owned 27,277 shares of Supernus common stock.
Georges Gemayel filed a Form 144 reporting planned and recent sales of common stock. The filing lists a sale on 03/05/2026 of 10,000 shares for $537,117.00. It also shows securities to be sold from exercises: 3,787 shares by exercise on 03/06/2026 and 5,000 shares previously exercised on 03/04/2026.
The notice references an exercise under a registered plan and cash transactions; timing and cash‑flow recipients are described in the entries tied to those exercise dates.
Supernus Pharmaceuticals President and CEO Jack A. Khattar reported the acquisition of 38,640 Performance Share Units at a price of $0.00 per unit. These units were awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives set on June 24, 2024.
SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec acquired performance share units. On the reported transaction date, 3,000 performance share units were credited to his direct holdings at no exercise price. According to a footnote, these units were originally awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives established on June 24, 2024.
SUPERNUS PHARMACEUTICALS, INC. reported an insider equity award for senior vice president and Chief Technology Operations Officer Frank Mottola. He acquired 3,750 Performance Share Units at a stated price of $0.00 per unit, leaving him with 3,750 such derivative securities held directly after the transaction.
According to the footnote, these Performance Share Units were originally awarded on February 23, 2023, with individual performance objectives for a defined performance period established on June 12, 2023. A portion of that award vested upon achievement of these objectives, and the reported acquisition reflects this vesting-based grant.
Supernus Pharmaceuticals files its annual report describing a CNS-focused business built around branded neurology and psychiatry drugs plus a deep pipeline. The company markets Qelbree for ADHD, multiple Parkinson’s disease therapies (GOCOVRI, APOKYN, ONAPGO, XADAGO), epilepsy and migraine drugs Trokendi XR and Oxtellar XR, MYOBLOC for cervical dystonia and sialorrhea, and ZURZUVAE for postpartum depression.
A major 2025 milestone was acquiring Sage Therapeutics for $8.50 per share in cash (about $561 million) plus contingent value rights worth up to $3.50 per share (about $234 million) tied mainly to ZURZUVAE sales and Japanese approval milestones. Supernus shares ZURZUVAE economics in the U.S. with Biogen and licenses zuranolone rights in parts of Asia to Shionogi.
The company highlights late-stage R&D assets including SPN‑817 for epilepsy, SPN‑820 targeting treatment‑resistant depression via mTORC1 modulation, and SPN‑443, a triple reuptake inhibitor being developed for ADHD. Manufacturing is fully outsourced to global CMOs, and three large wholesalers together account for more than 76% of 2025 product revenue.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported routine equity compensation activity. On February 25, 2026, 1,875 restricted stock units were disposed of to the issuer and simultaneously settled into 1,875 shares of common stock as part of a vesting event.
In a separate transaction the same day, 977 shares of common stock were disposed of through a tax-withholding disposition at $50.69 per share to satisfy withholding obligations tied to the RSU vesting. After these transactions, Mottola directly owned 18,106 shares of common stock.
Supernus Pharmaceuticals Senior Vice-President & CFO Timothy C. Dec reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 25, 2,500 RSUs were settled into 2,500 shares of common stock, and 1,279 of those shares were withheld by the company to cover tax obligations at a price of $50.69 per share. After these transactions, Dec directly owned 5,115 shares of common stock. Each RSU represents one share of common stock and vests in four equal annual installments beginning on February 23, 2024.
SUPERNUS PHARMACEUTICALS, INC. Sr. VP of IP and CSO Padmanabh P. Bhatt reported equity award-related transactions. A grant of 1,250 shares of common stock was acquired at a price of $0.00, tied to restricted stock units that convert into one share each upon vesting.
On the same date, 1,250 restricted stock units were disposed back to the issuer and 650 shares of common stock at $50.69 were withheld by the company to cover tax obligations in connection with RSU vesting, rather than sold on the open market.